BELITE BIO INC - AMER
67,44
27-ноября-24 15:45:00
15 мин. задержка
Акции
+3,42
+5,34%
Сегодняшний диапазон
62,53 - 70,00
ISIN
N/A
Источник
NASDAQ
- Котировки
- Графики
Новости
- Статистика
-
04 май 2023 10:09:06 Источник Nasdaq GlobeNewswire
-
25 апр 2023 15:30:00 Источник Nasdaq GlobeNewswire
-
11 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire
-
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
31 мар 2023 18:03:37 Источник Nasdaq GlobeNewswire
-
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
31 мар 2023 11:57:14 Источник Nasdaq GlobeNewswire
-
18 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
20 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire
-
01 окт 2022 18:03:33 Источник Nasdaq GlobeNewswire
-
23 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
16 сен 2022 07:00:32 Источник Nasdaq GlobeNewswire
-
Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S.
22 авг 2022 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Reports First Half 2022 Operational Highlights and Financial Results
10 авг 2022 20:51:10 Источник Nasdaq GlobeNewswire
-
Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
01 авг 2022 15:10:00 Источник Nasdaq GlobeNewswire
-
19 июл 2022 15:05:33 Источник Nasdaq GlobeNewswire
-
Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
12 май 2022 15:30:00 Источник Nasdaq GlobeNewswire
-
05 май 2022 07:00:02 Источник Nasdaq GlobeNewswire
-
Belite Bio Announces Closing of $36 Million Initial Public Offering
03 май 2022 15:30:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Receives FDA Fast Track Designation For LBS-008
03 май 2022 05:50:00 Источник Nasdaq GlobeNewswire